Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board
The newly appointed members are:
Adi Barzel , Ph.D., President of theIsraeli Society of Gene andCell Therapy ; Senior Lecturer,Department of Biochemistry ,School of NeuroBiology, Biochemistry and Biophysics ,Tel Aviv University Gavin Dunn , M.D., Ph.D., Associate Professor of Neurological Surgery, Andrew M. andJane M. Bursky Center for Human Immunology and Immunotherapy Programs ,Washington University School of Medicine Matthew Porteus , M.D., Ph.D., Professor of Pediatrics (Stem Cell Transplantation),Stanford University Kole Roybal , Ph.D., Assistant Professor of Microbiology and Immunology,University of California ,San Francisco ; member of theParker Institute for Cancer Immunotherapy Helen Diller Comprehensive Cancer Center
“We are pleased to welcome Drs. Barzel, Dunn, Porteus and Roybal as our scientific advisors to guide the development of our programs,” said
Dr.
Dr.
Dr.
Dr.
About Ziopharm Oncology, Inc.
Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com
Forward-Looking Statements Disclaimer
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the Company's business, strategic and commercialization plans, including its goal of treating all solid tumors. Although Ziopharm’s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the
Investor Relations Contacts:
Ziopharm Oncology:
Chris Taylor
VP, Investor Relations and Corporate Communications
T: 617.502.1881
E: ctaylor@ziopharm.com
Managing Director
T: 617.308.4306
E: mmoyer@lifescicomms.com
Media Relations Contact:
T: 646.876.4932
E: pbursey@lifescicomms.com
Source: ZIOPHARM Oncology Inc